Whitepaper | 2/1/2023

High Points and Stumbling Blocks in Cell and Gene Therapy: Exiting 2022, Entering 2023

By Alicia Shields, PhD, Emmanuel Toroitich, PhD, Chris Biondi, Ned Wydysh, PhD, Vivek Mittal, PhD
During the pandemic, public attention on healthcare innovation helped promote a tsunami of investment into the biotech sector. In 2022, however, macroeconomic conditions have created significant investment headwinds for the industry, and CGT companies have not been spared. Companies have laid off employees, pivoted pipeline priorities, and redistributed resources in an attempt to remove organizational redundancies, create operational efficiencies, and reduce expenses.
Read here.

Share this: